Literature DB >> 6108620

Thymoxamine hydrochloride: an alpha-adrenergic blocker.

M Wand, W M Grant.   

Abstract

Thymoxamine is an alpha-adrenergic blocking agent which works by competitive antagonism of norepinephrine. It is the only alpha-adrenergic blocker available which has tolerable side effects when used as an ophthalmic solution. When used as a 0.5% solution it consistently produces miosis without affecting the intraocular pressure or the ciliary muscle-controlled facility of outflow. The only regularly reported side-effects at this concentration are transient burning and conjunctival hyperemia. Potential applications of thymoxamine include reversal of phenylephrine mydriasis, treatment of angle-closure glaucoma, treatment of persistent mydriasis after penetrating keratoplasty for keratoconus, reversal of lid retraction in thyroid ophthalmopathy, testing to differentiate angle-closure glaucoma from open-angle glaucoma with narrow angles, aiding in repositioning and maintaining the position of intraocular lenses, treatment of pigmentary glaucoma. Thymoxamine may also contribute to a better understanding of the adrenergic nervous system on aqueous dynamics.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6108620     DOI: 10.1016/0039-6257(80)90150-2

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  3 in total

1.  Evaluation of the effect of thymoxamine solution 0.5% on mydriasis induced by ibopamine solution 1%.

Authors:  F Drago; A Dal Bello; V Marino; R Pisati; E Lodola; P Barbieri
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration.

Authors:  Joon Mo Kim; Ki Ho Park; Chan Yun Kim; Hwang Ki Kim; Tae-Woo Kim; Mo Sae Kim
Journal:  Jpn J Ophthalmol       Date:  2011-06-17       Impact factor: 2.447

3.  Thymoxamine: a miotic for intraocular use.

Authors:  F Grehn; T Fleig; E Schwarzmüller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.